Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ono Hooks Up with UK Charities in Cancer Immunotherapy
March 28, 2019
- Daiichi Sankyo Kicks Off Asia PIII for Mirogabalin
March 28, 2019
- Chugai’s SMA Drug Risdiplam Gets Orphan Status
March 28, 2019
- JSR Enters Strategic Partnership with Dutch Institute in Oncology Field
March 28, 2019
- Astellas’ Vasomotor Symptom Treatment Fezolinetant Smashes Primary Goals in US PIIb Study
March 28, 2019
- Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- Fujifilm, NCC Join Hands for I/O Research, Combining Liposomes with Immune Checkpoint Inhibitors
March 27, 2019
- Boehringer’s Ofev Gets Orphan Status for ILD in Systemic Sclerosis
March 27, 2019
- Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
- Novartis to Tap Disease Registry for Kymriah’s All-Case PMS: Exec
March 26, 2019
- SanBio to Move Ahead with SB623 Development in Stroke after PII Miss: President
March 26, 2019
- Avanir’s Alzheimer’s Agitation Drug Hits Primary Goal in PIII
March 26, 2019
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Vimpat IV Version Hits Japan Market: UCB, Daiichi Sankyo
March 26, 2019
- Ono Chief Recounts Long and Winding Road of Opdivo Development, Thanks Kyoto Univ. Professor
March 25, 2019
- JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019
- Japan Biosimilar Market Could Grow Like in Europe If Incentives Improved: Sandoz Japan Chief
March 25, 2019
- Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
March 25, 2019
- Analyst Says Drug Makers Can’t Recoup Investment in Overcompetitive Oncology Arena
March 22, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…